Treatment of sebaceous gland hyperplasia by photodynamic therapy with 5-aminolevulinic acid and a blue light source or intense pulsed light source.
Treatment of SGH by ALA-PDT with Blue Light Source or Intense Pulsed Light Activation. Sebaceous gland hyperplasia (SGH) lesions often present as a sign of photoaging and have proven difficult to treat. Photodynamic therapy (PDT) may be an effective treatment option. Twelve patients with SGH received PDT with 5-aminolevulinic acid (ALA, Levulan Kerastick, DUSA Pharmaceuticals, Inc) photosensitizing agent topically applied with a 30- to 60-minute drug incubation period. Patients received either 405-420 nm blue light (ClearLight PhotoClearing System, CureLight, Lumenis) for 15 minutes or intense pulsed light (IPL), 500-1,200 nm and 550 nm cut-off filter (VascuLight System, Lumenis) according to a randomization protocol. ALA-PDT was administered once per month for 4 consecutive months. Progress was evaluated at 4 and 12 weeks after the final treatment. More than a 50% reduction in the number of SGH lesions was achieved for patients in both treatment arms without lesional recurrence during the treatment and follow-up periods. All treatments were well-tolerated. Adverse effects were limited to mild, transient erythema (n = 2) and blisters (n = 1), which resolved without sequelae. ALA-PDT with either blue light or IPL photoactivation may provide therapeutic benefit without significant adverse effects in patients with SGH.
Gold
Michael H
MH
Gold Skin Care Center, Nashville, TN 37215, USA. goldskin@goldskincare.com
Bradshaw
Virginia L
VL
Boring
Molly M
MM
Bridges
Tancy M
TM
Biron
Julie A
JA
Lewis
Tammy L
TL
D000279:Administration, Cutaneous; D000328:Adult; D000622:Aminolevulinic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005145:Face; D005260:Female; D006801:Humans; D006965:Hyperplasia / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D012625:Sebaceous Gland Diseases / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D017319:Photosensitizing Agents; D000622:Aminolevulinic Acid